UPDATE 1-Ardelyx's kidney disease drug reduces elevated phosphate levels in late-stage study [Yahoo! Finance News]
Ardelyx, Inc. (ARDX)
Last ardelyx, inc. earnings: 3/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ardelyx.com/investor-relations
Company Research
Source: Yahoo! Finance News
UPDATE 1-Ardelyx's kidney disease drug reduces elevated phosphate levels in late-stage study ds background, details from the release) Dec 3 Reuters) - Ardelyx Inc said on Tuesday its experimental drug succeeded in regulating elevated blood phosphate levels in patients with chronic kidney disease CKD) in a late-stage study. The treatment, tenapanor, showed a greater difference in serum phosphorus levels compared to placebo, the company said. Elevated phosphorus levels are common in CKD patients, especially those on dialysis, as their weak kidneys are unable to adequately eliminate phosphorus from the body. Despite treatment with phosphate binders, about 70% of CKD patients on dialysis continue to experience elevated phosphorus levels, also called hyperphosphatemia, at any point in time, the company said. Ardelyx in September said patients treated with tenapanor and phosphate binders, the only approved therapy for hyperphosphatemia, showed a significant reduction in serum phosphorus lev
Show less
Read more
Impact Snapshot
Event Time:
ARDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARDX alerts
High impacting Ardelyx, Inc. news events
Weekly update
A roundup of the hottest topics
ARDX
News
- Ardelyx down as H.C. Wainwright downgrades rating on anticipated Xphozah sales drop [Seeking Alpha]Seeking Alpha
- Ardelyx, Inc. (NASDAQ: ARDX) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating. They now have a $5.50 price target on the stock, down previously from $11.00.MarketBeat
- Ardelyx Responds to District Court Decision Granting Motion to Dismiss [Yahoo! Finance]Yahoo! Finance
- Ardelyx Responds to District Court Decision Granting Motion to DismissGlobeNewswire
- Ardelyx to Participate at the 2024 Jefferies London Healthcare ConferenceGlobeNewswire
ARDX
Earnings
- 10/31/24 - Beat
ARDX
Sec Filings
- 11/14/24 - Form 4
- 11/14/24 - Form SC
- 11/12/24 - Form 4
- ARDX's page on the SEC website